Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dagher, R.
Right arrow Articles by Pazdur, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dagher, R.
Right arrow Articles by Pazdur, R.
Clinical Cancer Research Vol. 8, 3034-3038, October 2002
© 2002 American Association for Cancer Research

Report from the FDA

Approval Summary

Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors1

Ramzi Dagher2, Martin Cohen, Gene Williams, Mark Rothmann, Jogarao Gobburu, Gabriel Robbie, Atiqur Rahman, Gang Chen, Ann Staten, Donna Griebel and Richard Pazdur

Division of Oncology Drug Products [R. D., M. C., A. S., D. G., R. P.], Division of Pharmaceutical, Evaluation 1 [G. W., J. G., G. R., A. R.], Division of Biometrics 1, Center for Drug Evaluation and Research [M. R., G. C.], United States Food and Drug Administration, Rockville, Maryland 20857

ABSTRACT

Purpose: Imatinib mesylate (Gleevec; Novartis, East Hanover, NJ)is a receptor tyrosine kinase inhibitor approved previously in 2001 by the United States Food and Drug Administration for the treatment of chronic myelogenous leukemia in blast crisis, accelerated phase, or in chronic phase after failure of IFN-{alpha} therapy. We review herein the clinical profile of this drug and the regulatory review leading to the approval of a supplemental New Drug Application for the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors (GISTs).

Experimental Design: We discuss the efficacy and side effects of imatinib mesylate in a Phase II trial of 147 patients with metastatic and/or unresectable malignant GISTs, the basis for marketing approval, and postmarketing commitments by the drug’s manufacturer.

Results: Imatinib was assessed in a single, open-label trial involving one European center and three centers in the United States. Seventy-three patients were randomly allocated to receive 400 mg of imatinib daily, and 74 patients received 600 mg daily. At the study report cutoff date, an objective response was confirmed in 56 patients; the overall response rate for the combined study arms was 38% (95% confidence interval, 30–46%). These responses were all partial responses. There was no statistically significant difference in response rates between the two dose groups. Adverse events included edema, fluid retention, nausea, vomiting, diarrhea, myalgias, skin rash, bone marrow suppression, bleeding, and elevations in aspartate aminotransferase, alanine aminotransferase, or bilirubin. Bleeding into the gastrointestinal tract or intratumoral sites occurred in 7 patients (5%) and was not correlated with thrombocytopenia or tumor bulk. The pharmacokinetics of imatinib in GIST patients were similar to those of chronic myelogenous leukemia patients.

Conclusions: On February 1, 2001, imatinib mesylate was approved by the United States Food and Drug Administration for the treatment of malignant metastatic and/or unresectable GISTs. The recommended dose is 400 or 600 mg daily.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Hu, R. M. Franke, K. K. Filipski, C. Hu, S. J. Orwick, E. A. de Bruijn, H. Burger, S. D. Baker, and A. Sparreboom
Interaction of Imatinib with Human Organic Ion Carriers
Clin. Cancer Res., May 15, 2008; 14(10): 3141 - 3148.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Hu, H. Niu, P. Minkin, S. Orwick, A. Shimada, H. Inaba, G. V.H. Dahl, J. Rubnitz, and S. D. Baker
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
Mol. Cancer Ther., May 1, 2008; 7(5): 1110 - 1120.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. A. Larson, B. J. Druker, F. Guilhot, S. G. O'Brien, G. J. Riviere, T. Krahnke, I. Gathmann, Y. Wang, and for the IRIS (International Randomized Interferon
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Blood, April 15, 2008; 111(8): 4022 - 4028.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. P. van Erp, H. Gelderblom, M. O. Karlsson, J. Li, M. Zhao, J. Ouwerkerk, J. W. Nortier, H.-J. Guchelaar, S. D. Baker, and A. Sparreboom
Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib
Clin. Cancer Res., December 15, 2007; 13(24): 7394 - 7400.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Carpinelli, R. Ceruti, M. L. Giorgini, P. Cappella, L. Gianellini, V. Croci, A. Degrassi, G. Texido, M. Rocchetti, P. Vianello, et al.
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
Mol. Cancer Ther., December 1, 2007; 6(12): 3158 - 3168.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Desai, S. Shankar, M. C. Heinrich, J. A. Fletcher, C. D. Fletcher, J. Manola, J. A. Morgan, C. L. Corless, S. George, K. Tuncali, et al.
Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors
Clin. Cancer Res., September 15, 2007; 13(18): 5398 - 5405.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. G. Roberts, A. F. Odell, E. M. Byrnes, R. M. Baleato, R. Griffith, A. B. Lyons, and L. K. Ashman
Resistance to c-KIT kinase inhibitors conferred by V654A mutation
Mol. Cancer Ther., March 1, 2007; 6(3): 1159 - 1166.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. L. Goodman, E. P. Rock, R. Dagher, R. P. Ramchandani, S. Abraham, J. V.S. Gobburu, B. P. Booth, S. L. Verbois, D. E. Morse, C. Y. Liang, et al.
Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma
Clin. Cancer Res., March 1, 2007; 13(5): 1367 - 1373.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. P. Rock, V. Goodman, J. X. Jiang, K. Mahjoob, S. L. Verbois, D. Morse, R. Dagher, R. Justice, and R. Pazdur
Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma
Oncologist, January 1, 2007; 12(1): 107 - 113.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Bihorel, G. Camenisch, G. Gross, M. Lemaire, and J.-M. Scherrmann
Influence of Hydroxyurea On Imatinib Mesylate (Gleevec) Transport at the Mouse Blood-Brain Barrier
Drug Metab. Dispos., December 1, 2006; 34(12): 1945 - 1949.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. W. Yip, X. Mao, P.Y. B. Au, D. W. Hedley, S. Chow, S. Dalili, J. D. Mocanu, C. Bastianutto, A. Schimmer, and F.-F. Liu
Benzethonium Chloride: A Novel Anticancer Agent Identified by Using a Cell-Based Small-Molecule Screen.
Clin. Cancer Res., September 15, 2006; 12(18): 5557 - 5569.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
L Tornillo and L M Terracciano
An update on molecular genetics of gastrointestinal stromal tumours.
J. Clin. Pathol., June 1, 2006; 59(6): 557 - 563.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Goldberg, D. Niedzwiecki, M. Bertagnolli, A. W. Blackstock, J. E. Tepper, and R. J. Mayer
Cancer and leukemia group B gastrointestinal cancer committee.
Clin. Cancer Res., June 1, 2006; 12(11): 3589s - 3595s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. P. Raut, M. Posner, J. Desai, J. A. Morgan, S. George, D. Zahrieh, C. D.M. Fletcher, G. D. Demetri, and M. M. Bertagnolli
Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors
J. Clin. Oncol., May 20, 2006; 24(15): 2325 - 2331.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
O. Potapova, A. D. Laird, M. A. Nannini, A. Barone, G. Li, K. G. Moss, J. M. Cherrington, and D. B. Mendel
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248
Mol. Cancer Ther., May 1, 2006; 5(5): 1280 - 1289.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H.-P. Gschwind, U. Pfaar, F. Waldmeier, M. Zollinger, C. Sayer, P. Zbinden, M. Hayes, R. Pokorny, M. Seiberling, M. Ben-Am, et al.
METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS
Drug Metab. Dispos., October 1, 2005; 33(10): 1503 - 1512.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
F. Petti, A. Thelemann, J. Kahler, S. McCormack, L. Castaldo, T. Hunt, L. Nuwaysir, L. Zeiske, H. Haack, L. Sullivan, et al.
Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930
Mol. Cancer Ther., August 1, 2005; 4(8): 1186 - 1197.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J.-Y. Blay, S. Bonvalot, P. Casali, H. Choi, M. Debiec-Richter, A. P. Dei Tos, J.-F. Emile, A. Gronchi, P. C. W. Hogendoorn, H. Joensuu, et al.
Consensus meeting for the management of gastrointestinal stromal tumors * Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO
Ann. Onc., April 1, 2005; 16(4): 566 - 578.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
U. De Giorgi and J. Verweij
Imatinib and gastrointestinal stromal tumors: Where do we go from here?
Mol. Cancer Ther., March 1, 2005; 4(3): 495 - 501.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
K. Sandrasegaran, A. Rajesh, J. Rydberg, D. A. Rushing, F. M. Akisik, and J. D. Henley
Gastrointestinal Stromal Tumors: Clinical, Radiologic, and Pathologic Features
Am. J. Roentgenol., March 1, 2005; 184(3): 803 - 811.
[Full Text] [PDF]

Home page
 JCOHome page
S. J. Hotte, E. W. Winquist, E. Lamont, M. MacKenzie, E. Vokes, E. X. Chen, S. Brown, G. R. Pond, A. Murgo, and L. L. Siu
Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study
J. Clin. Oncol., January 20, 2005; 23(3): 585 - 590.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. Dagher, J. Johnson, G. Williams, P. Keegan, and R. Pazdur
Accelerated Approval of Oncology Products: A Decade of Experience
J Natl Cancer Inst, October 20, 2004; 96(20): 1500 - 1509.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. F. Smith, J. M. Bullock, B. M. Booker, C. E. Haas, C. S. Berenson, and W. J. Jusko
Induction of imatinib metabolism by hypericum perforatum
Blood, August 15, 2004; 104(4): 1229 - 1230.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Simon, S. Panussis, R. Maurer, H. Spichtin, K. Glatz, C. Tapia, M. Mirlacher, A. Rufle, J. Torhorst, and G. Sauter
KIT (CD117)-Positive Breast Cancers Are Infrequent and Lack KIT Gene Mutations
Clin. Cancer Res., January 1, 2004; 10(1): 178 - 183.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. K. Rowinsky
Signal Events: Cell Signal Transduction and Its Inhibition in Cancer
Oncologist, December 1, 2003; 8(90003): 5 - 17.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. G. Moss, G. C. Toner, J. M. Cherrington, D. B. Mendel, and A. D. Laird
Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans
J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 476 - 480.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. U. Lin, S. Sarantopoulos, J. R. Stone, I. Galinsky, R. M. Stone, D. J. Deangelo, and R. J. Soiffer
Fatal hepatic necrosis following imatinib mesylate therapy
Blood, November 1, 2003; 102(9): 3455 - 3456.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Gorden, I. Osman, W. Gai, D. He, W. Huang, A. Davidson, A. N. Houghton, K. Busam, and D. Polsky
Analysis of BRAF and N-RAS Mutations in Metastatic Melanoma Tissues
Cancer Res., July 15, 2003; 63(14): 3955 - 3957.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. R. Johnson, P. Bross, M. Cohen, M. Rothmann, G. Chen, A. Zajicek, J. Gobburu, A. Rahman, A. Staten, and R. Pazdur
Approval Summary: Imatinib Mesylate Capsules for Treatment of Adult Patients with Newly Diagnosed Philadelphia Chromosome-positive Chronic Myelogenous Leukemia in Chronic Phase
Clin. Cancer Res., June 1, 2003; 9(6): 1972 - 1979.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.